JPRN-jRCT2080225041已完成3 期
Phase III Study of HP-3150 in Patients with Humeroscapular Periarthritis, Cervico-omo-brachial Syndrome and Tenosynovitis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 342
研究概览
简要总结
The change in the pain VAS score at week 2 showed greater improvement in the 150-mg group than in the placebo group. The efficacy of HP-3150 was confirmed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •A patient who was clinically diagnosed with humeroscapular periarthritis, cervico-omo-brachial syndrome, or tenosynovitis not less than 4 weeks ago.
- •- A patient who has been treated with NSAIDs or acetaminophen for humeroscapular periarthritis, cervico-omo-brachial syndrome, or tenosynovitis for not less than 2 weeks and has not changed their dosage and dose regimen within 2 weeks.
排除标准
- •- A patient whose pain at the site of assessment is thought to be due to visceral disease, bone fracture, trauma, infection, tumor, rheumatoid arthritis, gout, or calcific tendonitis.
- •- A patient in whom pain in the sites of assessment cannot be assessed appropriately because she/he suffers pain due to complications.
- •- A patient with serious blood abnormality, liver disorder, renal disorder, hypertension, cardiac dysfunction, or other clinically problematic complications.
- •- A patient with malignancy.
- •- A patient with peptic ulcer.
- •- A patient with current or past history of aspirin-induced asthma.
- •- A patient with past history of hypersensitivity to NSAIDs.
- •- A patient who is pregnant, parturient, suspected of being pregnant, or breast-feeding.
- •- A patient who is known to have dermal sensitivity to external preparations or tapes such as adhesive tapes.
- •- A patient in whom a planned site of application cannot be secured due to skin abnormality, tattoos or birthmarks, or a patient who frequently gets tanned.
研究者
相似试验
已完成
3 期
Phase III Study of HP-3150 in Patients with Low Back PaiJPRN-jRCT2080225040Hisamitsu Pharmaceutical Co., Inc.965
未知
2 期
Phase II clinical study of HP-3150 in patients with low back pain.ow back painJPRN-jRCT2080222960Hisamitsu Pharmaceutical Co., Inc
未知
2 期
Phase 2/3 clinical study of HP-3150 in patients with cancer pain.Cancer painJPRN-jRCT2080222905Hisamitsu Pharmaceutical Co., Inc
已完成
2 期
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationCystic FibrosisNCT02709109Parion Sciences147
已完成
3 期
Safety and Efficacy in Adult Subjects With Acute MigrainesMigraine, With or Without AuraNCT03237845Pfizer1,499